Business context and reporting period
The supplied filing is Predictive Oncology Inc. (NASDAQ: POAI)’s Form 10-K for the fiscal year ended December 31, 2022, not a filing for “Axe Compute Inc.” The company applies AI and tumor data to oncology drug development and also operates 3D tumor-modeling, biologics formulation, clinical testing, and STREAMWAY medical-fluid-disposal businesses. The filing describes four reportable segments: Helomics, zPREDICTA, Soluble, and Skyline. Management says it plans to focus resources on AI-enabled oncology drug development and biopharma partnerships. No standalone fourth-quarter financial results are provided in the supplied text.
Financial highlights
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $1.51 million | $1.42 million |
| Gross profit / margin | $1.00 million / 66% | $0.93 million / 66% |
| Operating loss | $26.03 million | $20.43 million |
| Net loss | $25.74 million | $19.66 million |
| Loss per share, basic and diluted | $0.35 | $0.36 |
| Cash used in operating activities | $12.37 million | $12.21 million |
| Cash and cash equivalents at year-end | $22.07 million | $28.20 million |
Revenue increased by $84,779. Skyline generated $1.06 million, zPREDICTA $352,379, Soluble $82,301, and Helomics $6,397 in 2022. Skyline sold 7 STREAMWAY units, compared with 15 in 2021. The company reported current assets of $23.36 million and current liabilities of $3.88 million at year-end, with total liabilities of $3.97 million, including lease liabilities. It reported no material off-balance-sheet transactions. Management stated existing capital resources were expected to support its operating plan for the next twelve months and beyond, while noting potential additional financing needs.
Material changes versus 2021
- Net loss widened by about $6.08 million as operating loss increased; revenue growth was modest and gross margin was unchanged.
- 2022 included $7.23 million of goodwill impairment, $3.35 million of intangible-asset impairment, and $185,469 of tangible-asset impairment. The zPREDICTA goodwill and intangible assets were reduced to zero.
- Operations expense rose to $3.80 million and sales and marketing expense to $1.36 million, reflecting increased staffing, laboratory costs, and commercial activity.
- Financing provided $6.72 million in 2022, compared with $50.34 million in 2021. The May 2022 offerings issued 12.0 million shares at $0.60 per share and included warrants; certain existing warrants were repriced to $0.70. Common shares outstanding increased from 65.6 million at year-end 2021 to 78.8 million at year-end 2022.
Outlook, risks, and unusual items
- The company has a long history of losses and negative operating cash flow and said it expected net losses to continue at least through the remainder of 2023. Its oncology drug-discovery business has not generated significant revenue to date, and commercial execution remains uncertain.
- Management cited COVID-era supply-chain and staffing disruption, conservative customer spending, and suppliers’ requests for pre-delivery deposits. Other key risks include competition, dependence on financing, regulatory requirements, sole-source suppliers for some testing materials, and integration of acquired businesses.
- Nasdaq had granted an extension through May 8, 2023 to regain the $1.00 minimum bid-price requirement. The company said it would consider a reverse stock split if needed. The filing also disclosed a subsequent preferred-stock dividend carrying voting rights tied to a proposed reverse split.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2022 because of a material weakness: insufficient accounting resources with adequate U.S. GAAP expertise for complex transactions. Management planned to add qualified accounting staff. The independent auditor gave an unqualified opinion on the financial statements but did not audit internal-control effectiveness.
- Substantial tax-loss carryforwards are subject to potential ownership-change limits under Sections 382 and 383; the company had not completed its analysis of those limitations. The filing also noted that certain STREAMWAY patents begin to expire in 2023.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Predictive Oncology Inc. (POAI), despite the request metadata naming Axe Compute Inc.
- Assess cash burn and financing capacity against the $22.07 million year-end cash balance, ongoing losses, and management’s stated runway; verify subsequent financing and cash use.
- Review the terms and potential dilution from the 36.33 million outstanding warrants, the May 2022 warrant repricing, and subsequent share issuances.
- Track Nasdaq bid-price compliance and the status and terms of the proposed reverse split and related preferred-stock voting arrangement.
- Monitor whether the material weakness is remediated and whether impairment charges, weak segment revenue, and the strategic refocus affect future operating performance.